Home > Insider Trading > Filing (0000919574-15-008284)

Filing Details

Accession Number:: 0000919574-15-008284
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-11-17 17:08:18
Reporting Period:: 2015-11-13

Filing Date:: 2015-11-17
Accepted Time:: 2015-11-17 17:08:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1157601	Synta Pharmaceuticals Corp	SNTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1325713	Bruce Kovner	C/O Caxton Corporation 731 Alexander Road, Bldg. 2 Princeton NJ 08540		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2015-11-13	507,788	$0.43	1,817,255	No	4	S	Indirect	By CxSynta LLC
Common Stock	Disposition	2015-11-16	15,530	$0.44	1,801,725	No	4	S	Indirect	By CxSynta LLC
Common Stock	Disposition	2015-11-17	700,618	$0.42	1,101,107	No	4	S	Indirect	By CxSynta LLC

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By CxSynta LLC
No	4	S	Indirect	By CxSynta LLC
No	4	S	Indirect	By CxSynta LLC

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,092,677	Direct
Common Stock	2,279,146	Indirect	By Wife
Common Stock	11,399,464	Indirect	By KFO Holdings LLC
Common Stock	5,460,000	Indirect	By OB Select Opportunities, LLC
Common Stock	4,000,000	Indirect	By Kovner 2015-A Investment Trust
Common Stock	3,100,000	Indirect	By Kovner 2012 Family Trust B

Footnotes

This constitutes the weighted average sale price. The prices range from $0.43 to $0.4498. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This constitutes the weighted average sale price. The prices range from $0.43 to $0.4497. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This constitutes the weighted average sale price. The prices range from $0.4002 to $0.4388. The Reporting Person will provide upon request by the Securities and Exchange Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
These shares are owned directly by CxSynta LLC and indirectly by the Reporting Person as chairman and sole shareholder of Caxton Corporation, the managing member of CxSynta LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of the beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These securities are owned by the wife of the Reporting Person and her estate planning vehicles.
These shares are owned directly by KFO Holdings LLC and indirectly by the Reporting Person as chairman and sole shareholder of Caxton Corporation, the manager of KFO Holdings LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
These shares are owned directly by OB Select Opportunities, LLC and indirectly by the Reporting Person as chairman and sole shareholder of Caxton Corporation, the manager of OB Select Opportunities, LLC. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.